Glenmark
Pharmaceuticals Europe Ltd. has unveiled a generic version of Seretide
Accuhaler in Denmark. Glenmark on Wednesday said this was the company’s first
inhaled respiratory product introduction in Europe. It is the first generic
firm to get regulatory approval for substitution in Denmark for the generic
version of GlaxoSmithKline’s Seretide Accuhaler, according to a statement from
Glenmark.Glenmark had entered into a strategic development and licensing
agreement with Celon Pharma S.A. to develop and market the generic version –
Fluticasone/Salmeterol dry powder inhaler in 15 European countries.
The
Fluticasone/Salmeterol dry powder inhaler is a combination product for the
treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark
had already received National Marketing Authorisations for the product in
Sweden, Finland, Norway and Iceland.
“Denmark is the
first country in Europe where Glenmark has launched its generic
Fluticasone/Salmeterol Dry powder Inhaler (DPI) and we plan to commercialize
this product across the Nordics in the near future,” said Achin Gupta,
Executive Vice President and Business Head of Europe and Latin America,
Glenmark Pharmaceuticals Ltd.
The release,
quoting IQVIA data, said Fluticasone/Salmeterol DPI had sales of $ 864 million
in Europe during the 12 month ended September 2017.
http://www.thehindu.com/business/glenmark-introduces-inhaler-in-denmark/article23906183.ece
